Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 5
Opinion
Video
EMERALD Study Design and Results for Elacestrant
Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice.
- Please provide some background on the EMERALD trial evaluating elacestrant in HR+ HER2- mBC as well as subgroup data in patients with visceral metastases (Shah et al. J Clin Oncol. 2024)
- How have the EMERALD trial impacted your use of Elacestrant in clinical practice, particularly in terms of patients’ selection and treatment sequencing?
- What are your impressions of the overall and subgroup data from EMERALD? Does it expand the ideal patient population for elacestrant?
- For a patient with metastatic breast cancer to bones, liver, and lungs who has an ESR1 mutation, how does this inform treatment selection between continuing endocrine therapy versus switching to other targeted agents or chemotherapy?
- Would elacestrant be an ideal next line treatment for this patient?
Related Videos
Related Content
